Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.9042 -0.0345 (-3.68%)
Streaming Delayed Price Updated: 2:07 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
From Invivyd
Via GlobeNewswire
News headline image
IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024 ↗
IVVD stock results show that Invivyd met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023 ↗
IVVD stock results show that Invivyd missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
From Invivyd
Via GlobeNewswire
News headline image
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
IVVD Stock Earnings: Invivyd Misses EPS, Misses Revenue for Q2 2024 ↗
IVVD stock results show that Invivyd missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate at the Jefferies Global Healthcare Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Elects Two New Independent Members to its Board of Directors
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces CEO Transition
Jeremy Gowler appointed Interim CEO 
From Invivyd
Via GlobeNewswire
News headline image
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
From Invivyd
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.